<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934748</url>
  </required_header>
  <id_info>
    <org_study_id>GUARDIAN, Vasopressor</org_study_id>
    <nct_id>NCT04934748</nct_id>
  </id_info>
  <brief_title>GUARDIAN (NCT04884802) Sub-study, Phenylephrine v. Norepinephrine</brief_title>
  <official_title>GUARDIAN (NCT04884802) Sub-study Comparing Phenylephrine and Norepinephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients participating in the underlying GUARDIAN trial (NCT04884802) will be&#xD;
      additionally randomized to norepinephrine or phenylephrine infusion to maintain the&#xD;
      designated target intraoperative mean arterial pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients participating in the underlying GUARDIAN trial (NCT04884802) will be randomized to:&#xD;
      1) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed&#xD;
      resumption of chronic antihypertensive medications, and a target ward systolic pressure of at&#xD;
      least 110 mmHg (tight pressure management); or, 2) routine intraoperative blood pressure&#xD;
      management and prompt resumption of chronic antihypertensive medications (routine pressure&#xD;
      management). Patients participating in this sub-study will be additionally randomized to&#xD;
      norepinephrine or phenylephrine infusion to maintain the designated target intraoperative&#xD;
      mean arterial pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major perfusion-related complications</measure>
    <time_frame>30 days after major non-cardiac surgery</time_frame>
    <description>Composite of major perfusion-related complications (Myocardial injury, stroke, non-fatal cardiac arrest, stage 2-3 acute kidney injury, sepsis, and death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative delirium</measure>
    <time_frame>4 Postoperative hospital days</time_frame>
    <description>Three dimensional Confusion Assessment Method (3D CAM)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">6254</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Tight Pressure Management with phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tight Pressure Management with norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Pressure Management with phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pressure maintenance with phenylephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Pressure Management with norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pressure maintenance with norepinephrine infusion at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
    <arm_group_label>Tight Pressure Management with phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
    <arm_group_label>Tight Pressure Management with norepinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
    <arm_group_label>Routine Pressure Management with phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.</description>
    <arm_group_label>Routine Pressure Management with norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 45 years old;&#xD;
&#xD;
          -  Scheduled for major noncardiac surgery expected to last at least 2 hours;&#xD;
&#xD;
          -  Having general anesthesia, neuraxial anesthesia, or the combination;&#xD;
&#xD;
          -  Expected to require at least overnight hospitalization (planned ICU admission is&#xD;
             acceptable);&#xD;
&#xD;
          -  Are designated ASA physical status 2-4 (ranging from mild systemic disease through&#xD;
             severe systemic disease that is a constant threat to life);&#xD;
&#xD;
          -  Chronically taking at least one anti-hypertensive medication;&#xD;
&#xD;
          -  Expected to have direct intraoperative blood pressure monitoring with an arterial&#xD;
             catheter;&#xD;
&#xD;
          -  Cared for by clinicians willing to follow the GUARDIAN protocol;&#xD;
&#xD;
          -  Subject to at least one of the following risk factors:&#xD;
&#xD;
          -  Age &gt;65 years;&#xD;
&#xD;
          -  History of peripheral arterial surgery;&#xD;
&#xD;
          -  History of coronary artery disease;&#xD;
&#xD;
          -  History of stroke or transient ischemic attack;&#xD;
&#xD;
          -  Serum creatinine &gt;175 µmol/L (&gt;2.0 mg/dl);&#xD;
&#xD;
          -  Diabetes requiring medication;&#xD;
&#xD;
          -  Current smoking or 15 pack-year history of smoking tobacco;&#xD;
&#xD;
          -  Scheduled for major vascular surgery;&#xD;
&#xD;
          -  Body mass index ≥35 kg/m2;&#xD;
&#xD;
          -  Preoperative high-sensitivity troponin T &gt;14 ng/L or troponin I equivalent, defined as&#xD;
             ≥15 ng/L (Abbott assay),77 19 ng/L (Siemens assay, [Borges, unpublished]), or 25% of&#xD;
             the 99% percentile for other assays;&#xD;
&#xD;
          -  B-type natriuretic protein (BNP) &gt;80 ng/L or N-terminal B-type natriuretic protein&#xD;
             (NT-ProBNP) &gt;200 ng/L.78,79&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are scheduled for carotid artery surgery;&#xD;
&#xD;
          -  Are scheduled for intracranial surgery;&#xD;
&#xD;
          -  Are scheduled for partial or complete nephrectomy;&#xD;
&#xD;
          -  Are scheduled for pheochromocytoma surgery;&#xD;
&#xD;
          -  Are scheduled for liver or kidney transplantation;&#xD;
&#xD;
          -  Require preoperative intravenous vasoactive medications;&#xD;
&#xD;
          -  Have a condition that precludes routine or tight blood pressure management such as&#xD;
             surgeon request for relative hypotension;&#xD;
&#xD;
          -  Require beach-chair positioning;&#xD;
&#xD;
          -  Have a documented history of dementia;&#xD;
&#xD;
          -  Have language, vision, or hearing impairments that may compromise cognitive&#xD;
             assessments;&#xD;
&#xD;
          -  Have contraindications to norepinephrine or phenylephrine per clinician judgement;&#xD;
&#xD;
          -  Have previously participated in the GUARDIAN trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

